Mark A. Sutton VIEW CLINICAL PROFILE

Mark A. Sutton, MD

Adjunct Professor of Urology, Academic Institute
Houston Methodist


VIEW CLINICAL PROFILE
Biography

Dr. Mark Sutton is the vice chairman of the Houston Methodist Department of Urology and the site director at the Houston Metro Urology Ambulatory Surgery Site for the Houston Methodist Urology Residency. He is an associate professor of urology at Baylor College of Medicine, Scott Department of Urology and is the president-elect of the Texas Urologic Society, which represents all urologists in the State of Texas. His practice style is to treat patients like he would treat himself or a member of his own family, with compassion and state-of-the-art urologic service.

Description of Research

Dr. Sutton’s areas of interest include minimally-invasive surgery (laparoscopy); Da Vinci Robotic surgery for prostate cancer, bladder cancer, kidney cancer, UPJ obstruction; cryoablative (freezing) and HIFU therapy for prostate/kidney cancer; vasectomy and microscopic vasectomy reversals; ESWL and endoscopic stone laser stone removal techniques; penile prostheses for erectile problems and artificial urinary sphincters for urine incontinence; interstim neuromodulation (bladder pacemaker) implantation and botox implantation for overactive bladder; and green-light laser surgery for prostate enlargement.

Publications

Prospective Trial of Water Vapor Thermal Therapy for Treatment of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia in Subjects with a Large Prostate: 6- and 12-month Outcomes
Rezum Clinical Trials Group 2023, , European Urology Open Science, vol. 58, pp. 64-72. https://doi.org/10.1016/j.euros.2023.10.006

Five-year outcomes for Aquablation therapy compared to TURP: results from a double-blind, randomized trial in men with LUTS due to BPH
Gilling, PJ, Barber, N, Bidair, M, Anderson, P, Sutton, M, Aho, T, Kramolowsky, E, Thomas, A, Kaufman, RP, Badlani, G, Plante, M, Desai, M, Doumanian, L, Te, AE & Roehrborn, CG 2022, , Canadian Journal of Urology, vol. 29, no. 1, pp. 10960-10968.

Three-year outcomes after Aquablation therapy compared to TURP: results from a blinded randomized trial
Gilling, P, Barber, N, Bidair, M, Anderson, P, Sutton, MA, Aho, T, Kramolowsky, E, Thomas, A, Cowan, B, Kaufman, RP, Trainer, A, Arther, A, Badlani, G, Plante, M, Desai, M, Doumanian, L, Te, AE, DeGuenther, M & Roehrborn, C 2020, , The Canadian journal of urology, vol. 27, no. 1, pp. 10072-10079.

Two-Year Outcomes After Aquablation Compared to TURP: Efficacy and Ejaculatory Improvements Sustained
Gilling, P, Barber, N, Bidair, M, Anderson, P, Sutton, MA, Aho, T, Kramolowsky, E, Thomas, A, Cowan, B, Kaufman, RP, Trainer, A, Arther, A, Badlani, G, Plante, M, Desai, M, Doumanian, L, Te, AE, DeGuenther, M & Roehrborn, C 2019, , Advances in Therapy, vol. 36, no. 6, pp. 1326-1336. https://doi.org/10.1007/s12325-019-00952-3

Randomized Controlled Trial of Aquablation versus Transurethral Resection of the Prostate in Benign Prostatic Hyperplasia: One-year Outcomes
Gilling, PJ, Barber, N, Bidair, M, Anderson, P, Sutton, M, Aho, T, Kramolowsky, E, Thomas, A, Cowan, B & Roehrborn, C 2019, , Urology, vol. 125, pp. 169-173. https://doi.org/10.1016/j.urology.2018.12.002

WATER: A Double-Blind, Randomized, Controlled Trial of Aquablation® vs Transurethral Resection of the Prostate in Benign Prostatic Hyperplasia
Gilling, P, Barber, N, Bidair, M, Anderson, P, Sutton, M, Aho, T, Kramolowsky, E, Thomas, A, Cowan, B, Kaufman, RP, Trainer, A, Arther, A, Badlani, G, Plante, M, Desai, M, Doumanian, L, Te, AE, DeGuenther, M & Roehrborn, C 2018, , Journal of Urology, vol. 199, no. 5, pp. 1252-1261. https://doi.org/10.1016/j.juro.2017.12.065

Symptom relief and anejaculation after aquablation or transurethral resection of the prostate: subgroup analysis from a blinded randomized trial
Plante, M, Gilling, P, Barber, N, Bidair, M, Anderson, P, Sutton, M, Aho, T, Kramolowsky, E, Thomas, A, Cowan, B, Kaufman, RP, Trainer, A, Arther, A, Badlani, G, Desai, M, Doumanian, L, Te, AE, DeGuenther, M & Roehrborn, C 2019, , BJU International, vol. 123, no. 4, pp. 651-660. https://doi.org/10.1111/bju.14426

Procedural techniques and multicenter postmarket experience using minimally invasive convective radiofrequency thermal therapy with Rezum system for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia
Darson, MF, Alexander, EE, Schiffman, ZJ, Lewitton, M, Light, RA, Sutton, MA, Delgado-Rodriguez, C & Gonzalez, RR 2017, , Research and Reports in Urology, vol. 9, pp. 159-168. https://doi.org/10.2147/RRU.S143679

In vivo adenovirus-mediated suicide gene therapy of orthotopic bladder cancer
Sutton, MA, Freund, CTM, Berkman, SA, Dang, TD, Kattan, MW, Wheeler, TM, Rowley, DR & Lerner, SP 2000, , Molecular Therapy, vol. 2, no. 3, pp. 211-217. https://doi.org/10.1006/mthe.2000.0119

Adenovirus-mediated combination suicide and cytokine gene therapy for bladder cancer
Freund, CTF, Sutton, MA, Dang, T, Contant, CF, Rowley, D & Lerner, SP 2000, , Anticancer Research, vol. 20, no. 3 A, pp. 1359-1365.

Continent ileocecal augmentation cystoplasty
Sutton, MA, Hinson, JL, Nickell, KG & Boone, TB 1998, , Spinal Cord, vol. 36, no. 4, pp. 246-251. https://doi.org/10.1038/sj.sc.3100500

Adenovirus-mediated suicide gene therapy for experimental bladder cancer
Sutton, MA, Berkman, SA, Chen, S-H, Block, A, Dang, TD, Kattan, MW, Wheeler, TM, Rowley, DR, Woo, SLC & Lerner, SP 1997, , Urology, vol. 49, no. 2, pp. 173-180. https://doi.org/10.1016/S0090-4295(96)00560-2

Intracranial metastases as the first manifestation of prostate cancer
Sutton, MA, Watkins, HL, Green, LK & Kadmon, D 1996, , Urology, vol. 48, no. 5, pp. 789-793. https://doi.org/10.1016/S0090-4295(96)00238-5

VIEW FULL PUBLICATIONS